The immune mechanism and target effects of Tislelizumab

Tislelizumab (Tislelizumab) is an innovative humanized immune checkpoint inhibitor that mainly targets the programmed death receptor -1 (PD-1) protein. As an immunotherapy drug, tislelizumab relieves the suppression of the immune system by tumors and activates the patient's own immune cells to effectively attack and control tumors.

Specifically, PD-1 is an inhibitory receptor expressed on the surface of T cells. Its normal function is to maintain self-tolerance of the immune system and prevent the occurrence of autoimmune diseases. However, many tumor cells express PD-L1 or PD-L2 ligands, bind to the PD-1 receptor, and inhibit the activation and proliferation of T cells, thus evading the surveillance of the immune system. Tislelizumab, as a PD-1 inhibitor, can block the binding of PD-1 to its ligands and restore the immune function of T cells.

Tislelizumab has been optimized in structural design to reduce the binding ability of the antibody to macrophage Fcγ receptors, thereby reducing non-specific clearance of T cells and improving the safety and durability of the drug. By precisely targeting PD-1, tislelizumab effectively activates tumor-infiltrating lymphocytes (TILs), enhances the body's anti-tumor immune response, promotes tumor cell apoptosis and inhibits tumor growth.

In short, tislelizumab targets the PD-1 immune checkpoint, relieves tumor immune escape, and restarts the anti-cancer ability of the patient's immune system, making it an important choice in the current treatment of various malignant tumors. Its unique immune mechanism and optimized design bring better efficacy and lower risk of side effects to patients, promoting the continuous development of tumor immunotherapy.

Reference materials:https://www.drugs.com

xa0